The Ganja Club Weekly Digest
This week, the most significant development in medical cannabis comes not from a clinical trial or a regulatory filing, but from the voices of patients themselves. A growing body of evidence suggests that lived experience is proving a more powerful force for destigmatisation than any amount of laboratory data. As the sector matures, the question is no longer whether cannabis works, but how best to integrate patient testimony into the broader medical and policy conversation.
UK News
A provocative analysis from Cannabis Health News has raised questions about the concentration of prescribing power in England. The report suggests that as few as ten doctors may be responsible for half of all medical cannabis prescriptions in the country. While the figure is disputed, it underscores a persistent problem: access remains heavily dependent on a small number of specialist clinicians, limiting patient choice and slowing the rollout of a truly national service.
Two new studies have added to the evidence base for cannabis-based medicines. Research published this week indicates that cancer patients using cannabis extracts report meaningful improvements in symptom management, including pain and nausea. Separately, a study focusing on hypermobility patients found sustained pain relief from cannabis medicines, offering hope to a group that has historically struggled to find effective treatments. These findings, while preliminary, reinforce the case for broader prescribing in conditions where conventional options fall short.
International News
In the United States, the Drug Enforcement Administration has limited participation in its upcoming hearing on marijuana rescheduling to those opposed to the move. The decision has been criticised as a procedural manoeuvre that effectively excludes advocates of reform, raising questions about the fairness of the process. Meanwhile, the Supreme Court has affirmed that cannabis consumers retain their Second Amendment rights, a ruling that may have implications for employment and civil liberties in states where cannabis is legal.
Elsewhere in the US, Colorado has reported that cannabis use among teenagers continues its decade-long decline, challenging the narrative that legalisation leads to increased youth consumption. In Virginia, the governor has agreed to a revised measure for recreational sales, signalling a cautious step forward. Maine has enacted a law protecting medical cannabis patients from workplace discrimination, a move that could set a precedent for other states grappling with the tension between federal prohibition and state-level legalisation.
Internationally, a novel experiment in a US city has completed its first year: a basic income scheme funded entirely by cannabis tax revenue. City leaders have declared the programme a success, suggesting that the economic benefits of a regulated market can extend well beyond the industry itself.
Looking Ahead
Next week, attention will turn to the DEA’s rescheduling hearing, which may prove a pivotal moment for US cannabis policy. In the UK, the debate over prescribing concentration is unlikely to fade, and further patient-focused studies are expected. The Ganja Club will continue to monitor these developments with the rigour they deserve.
The Ganja Club weekly digest rounds up the most significant medical cannabis news every Friday. Based on 10 stories tracked this week. Get it by email →
